Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

#4447

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Aim(s): This study investigates the efficacy and adverse effects of XELOX in combination with Bevacizumab in Chinese patients with metastatic NETs, addressing a gap in domestic research.

Materials and methods: We identified patients with metastatic NETs treated with XELOX plus Bevacizumab at our hospital from February 28, 2024, to November 1, 2024, and collected data on efficacy and adverse reactions.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,